Chair of the ABPI Antibiotics Network Mark Lloyd Davies comments on the publication of Securing new drugs for future generations: The Pipeline of Antibiotics by Jim O’Neill Chair of The Review on Antimicrobial Resistance, (AMR).
13 May 2015 Posted in News Release By Press Office
Commenting on the publication of the report Mark said:
"Antibiotics play a crucial role in modern medicine, providing the platform for a wide range of medical interventions that would be impossible to perform due to the risk of infection. However, antibiotics continue to be undervalued and their price does not always reflect their value to society.
"As the O’Neill review team has argued, pharmaceutical companies and governments across the globe need to work together as a matter of urgency to create aligned incentives to encourage the development, manufacture and provision of much needed new antibiotics, along with changing behaviour around the use of existing medicines.
"This interim Report suggests that two funds are needed - a global AMR Innovation Fund ($2–5 billion) to de-risk R&D, to be paid for by the pharmaceutical industry, and a global reimbursement fund to pay for innovative antibiotics ($16–37 billion). We welcome the report’s focus on how to de-risk R&D and de-link reward for innovators from the use of the antibiotic in the market. It is important that the next phase of work by the O’Neill Review addresses how these funds will work in more detail and looks at potential gaps that these funds would leave unaddressed. For example, while the Global Innovation Fund would encourage early stage research and development, this would yield new treatments years from now. It is therefore important to also recognise the value of existing antibiotics and those in late stages of development.
"There are also issues to resolve about how the global reimbursement fund will work – who will pay for it? How will new antibiotics be judged to be of sufficient value to access the fund? Can it learn from the proven model of the Innovative Medicines Initiative where expertise, personnel and capital resource are just as important as funds?
"The ABPI Antibiotic Network views a new economic model for antibiotics as a crucial component of a sustainable landscape for antibiotic development, and supports an advanced market commitment model. This will reduce financial risk for healthcare services and innovators alike, while ensuring patients have access to new antibiotics.
"Antimicrobial resistance is a global issue, which requires a multi-stakeholder response. The pharmaceutical sector’s long history of research and development of successful antibiotics should not be overlooked. The industry will continue to work with academia, the UK Government and the healthcare sector to develop an alternative and sustainable economic model for antibiotics. We look forward to contributing to the Review’s ongoing work to address the growing challenge of AMR."